SPVN 50
Alternative Names: SPVN-50Latest Information Update: 31 Oct 2021
At a glance
- Originator SparingVision
- Developer Intellia Therapeutics; SparingVision
- Class Eye disorder therapies; RNA
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders